Neuland Laboratories Limited — Q1FY27 Earnings Call Summary

NEULANDLAB · Q1FY27 · Filed 10 Aug 2026

Key Takeaways

• Working capital days improved to 84 from 137 in FY26; capex INR121.6 Cr for R&D and peptide facilities
• FY27 growth expected around 20%, with no destocking risk in near term
• EBITDA margin guidance around 25% long term; current quarter margin partly due to favorable conditions
• Peptide plant commissioning next month; multiple projects lined up with commercial potential
• Commercial CMS growth driven by handful of molecules; 1-2 new commercializations expected next year
• Development pipeline improving; new molecules expected to replenish commercial base in 3-5 years
• Land acquisition ongoing for short-term expansion; long-term plans include new manufacturing sites
• Future capex to be larger and qualitatively different, focusing on complex modalities and possible geographic diversification
• Q1FY27 total income INR650.1 Cr +16.3% y-y; EBITDA INR231.1 Cr, margin 35.5%; PAT INR147.4 Cr
• Strategic collaboration with Gland Pharma for sterile APIs; asset-light partnership

📄 Source: View original transcript (PDF)

Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.